Nuvation Bio Inc 应付票据及应付账款 : $ 2.21 (2023年12月 最新)
Nuvation Bio Inc应付票据及应付账款(Accounts Payable)的相关内容及计算方法如下:
应付票据及应付账款是指公司欠供应商以信贷方式购买的商品和服务的任何款项,预计将在下一年或营业周期内支付。
截至2023年12月, Nuvation Bio Inc 过去一季度 的 应付票据及应付账款 为 $ 2.21。
点击上方“历史数据”快速查看Nuvation Bio Inc 应付票据及应付账款的历史走势;
点击上方“解释说明”快速查看关于Nuvation Bio Inc 应付票据及应付账款的详细说明;
点击上方“相关词条”快速查看与应付票据及应付账款相关的其他指标。
Nuvation Bio Inc 应付票据及应付账款 (NUVB.WS 应付票据及应付账款) 历史数据
Nuvation Bio Inc 应付票据及应付账款的历史年度,季度/半年度走势如下:
Nuvation Bio Inc 应付票据及应付账款 年度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2020-12 | 2021-12 | 2022-12 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
应付票据及应付账款 | 2.17 | 3.93 | 2.14 | 2.21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nuvation Bio Inc 应付票据及应付账款 季度数据 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
日期 | 2021-09 | 2021-12 | 2022-03 | 2022-06 | 2022-09 | 2022-12 | 2023-03 | 2023-06 | 2023-09 | 2023-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
应付票据及应付账款 | 5.16 | 3.93 | 9.67 | 12.73 | 3.00 | 2.14 | 2.95 | 2.58 | 2.37 | 2.21 |
Nuvation Bio Inc 应付票据及应付账款 (NUVB.WS 应付票据及应付账款) 解释说明
应付票据及应付账款是指公司欠供应商以信贷方式购买的商品和服务的任何款项,预计将在下一年或营业周期内支付。
Nuvation Bio Inc 应付票据及应付账款 (NUVB.WS 应付票据及应付账款) 相关词条
感谢查看价值大师中文站为您提供的Nuvation Bio Inc应付票据及应付账款的详细介绍,请点击以下链接查看与Nuvation Bio Inc应付票据及应付账款相关的其他词条:
Nuvation Bio Inc (NUVB.WS) 公司简介
一级行业:医疗保健
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
二级行业:生物科技
公司网站:https://www.nuvationbio.com
公司地址:1500 Broadway, Suite 1401, New York, NY, USA, 10036
公司简介:Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).